Health Policy
The Health Policy Track for 2022 marks the middle of a new five-year political cycle in the EU. This will be a cycle underpinned by challenges with regard to healthcare system sustainability, access and innovation, but which at the same time will be supported by an unprecedented commitment to healthcare from the European institutions in terms of policy, legislative proposals and funding.
Bold, ambitious initiatives such as those outlined in the Pharmaceutical strategy and which include the beating cancer plan, Europe’s digital strategy, AI strategy, and the European Strategy for data and associated European Health Data Space all hold major promise to help create a future proof European Healthcare framework which can support industry in promoting research and technologies that continue to benefit the lives of European citizens.
Featuring stakeholders from across the healthcare space including numerous European Commission officials on the panels and podium, the health policy track will provide valuable and future-looking perspectives on health policy in Europe with a specific focus on the need for fit for purpose frameworks and policies which keep pace with the rapid and exponential growth of innovation in the areas of medical science, digital health and data. Expect to navigate this track in a sequenced order, starting with how the future of medical science will look like, what will be the future trends in digital and data use in healthcare and concluding with how future proof are the current EU policies and systems.
Who is This Track Designed For?
Public affairs, governmental affairs and policy specialists, corporate affairs and communications professionals, consultants, lawyers and legal consultants, MEP assistants, trade association representatives, political advisors and aides and organisations involved in pharmaceutical and health policy.
The online program is now available. Explore the rich content we offer across 10 thought leadership tracks.
Topic Leaders
Thomas Brookland, MSc
Personalised Healthcare Policy Strategy Leader
F. Hoffmann-La Roche Ltd., Switzerland
Douglas Gregory
Senior Director, Government Affairs Strategy and Excellence
Bristol Myers Squibb, Belgium
Agenda
-
Day 1: Tuesday, March 29th
-
Day 2: Wednesday, March 30th
Cell & Gene Therapy – Blessing or Curse for Regulatory and HTA? A question of Uncertainties
Successful Integration of Digital Health Technologies to the Benefit of the Patients
Managing Project Orbis – Local & International Success Stories
-
Day 3: Thursday, March 31st
Future Proofing the Paediatric Regulation
Shaping the Regulatory Framework for Better Health in Europe
DIA Europe 2022 Highlights
It will provide updates on key developments on the GCP Renovation (ICH E6, ICH E8), Clinical Trial Regulation, the Clinical Trial Information System, data submission, transparency, navigating ethical approval, study design in the digital age, innovative clinical trial designs (umbrella and platform trials, patient centricity), digital tools in development and other hot topics. It should be a must-attend for optimising development programmes and identifying cost savings through efficiency and innovation.